Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs.
“We are excited to begin 2022 with a catalyst rich year that will be driven by our multiple TriTAC clinical programs, including advancing our HPN217 program into the next phase of development,” stated Julie Eastland, President and CEO, Harpoon Therapeutics. “We also expect to submit our first IND for HPN601, targeting EpCAM, from our ProTriTAC technology platform as well as advance an additional preclinical candidate into IND enabling studies as we continue to build out our future clinical pipeline.”
Anticipated 2022 Milestones
TriTAC Clinical Programs
- HPN328 – Continue dose escalation to determine RP2D by year-end 2022
- HPN217 – Select the RP2D and initiate dose expansion cohort during the first half of 2022
- HPN536 – Complete dose escalation by year-end 2022
- HPN424 – Complete dose escalation during the second half of 2022
Platform Technologies and Next Clinical Candidate
- HPN601 – IND submission by year-end 2022
- Platform technologies – Advance a clinical candidate into IND enabling studies during the second half of 2022
Corporate Update Events
- Harpoon will host an R&D Day during the first half of 2022
